A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
TNT
The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD
2 other identifiers
interventional
8,600
13 countries
309
Brief Summary
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Apr 1998
Longer than P75 for phase_4
309 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1998
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2004
CompletedFirst Submitted
Initial submission to the registry
May 16, 2006
CompletedFirst Posted
Study publicly available on registry
May 18, 2006
CompletedMay 3, 2007
May 1, 2007
May 16, 2006
May 1, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
The primary outcome is the time to occurrence of a major
cardiovascular event, defined as the composite outcome of the
following clinical endpoints
CHD death
Non-fatal/Non-procedure related MI
Resuscitated cardiac arrest or fatal/non-fatal stroke
Secondary Outcomes (7)
The occurrence of the following clinical events
Major coronary event (CHD death, non fatal myocardial infarction or resuscitated cardiac arrest)
any coronary event (major coronary event or CABG
PTCA, other revascularization procedure, procedure-related myocardial infarction, or documented angina)
cerebrovascular event (fatal or non fatal stroke, TIA)
- +2 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Men and women age 35-75 who have evident CHD
You may not qualify if:
- Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (314)
Pfizer Investigational Site
Alabaster, Alabama, 35007, United States
Pfizer Investigational Site
Birmingham, Alabama, 35205-4785, United States
Pfizer Investigational Site
Birmingham, Alabama, 35213, United States
Pfizer Investigational Site
Birmingham, Alabama, 35294-2041, United States
Pfizer Investigational Site
Hoover, Alabama, 35216, United States
Pfizer Investigational Site
Montgomery, Alabama, 36117, United States
Pfizer Investigational Site
Mesa, Arizona, 85202, United States
Pfizer Investigational Site
Mesa, Arizona, 85206, United States
Pfizer Investigational Site
Burbank, California, 91505, United States
Pfizer Investigational Site
Camp Pendleton, California, 92055, United States
Pfizer Investigational Site
Fresno, California, 93703, United States
Pfizer Investigational Site
La Jolla, California, 92037, United States
Pfizer Investigational Site
Loma Linda, California, 92354, United States
Pfizer Investigational Site
Los Angeles, California, 90017-2395, United States
Pfizer Investigational Site
Los Angeles, California, 90048, United States
Pfizer Investigational Site
Modesto, California, 95350, United States
Pfizer Investigational Site
Pasadena, California, 91105, United States
Pfizer Investigational Site
Rancho Mirage, California, 92270, United States
Pfizer Investigational Site
San Diego, California, 92134-3303, United States
Pfizer Investigational Site
San Francisco, California, 94143-0130, United States
Pfizer Investigational Site
San Francisco, California, 94143-0326, United States
Pfizer Investigational Site
Santa Rosa, California, 95403, United States
Pfizer Investigational Site
Stanford, California, United States
Pfizer Investigational Site
Aurora, Colorado, 80012, United States
Pfizer Investigational Site
Denver, Colorado, 80203, United States
Pfizer Investigational Site
Denver, Colorado, 80218, United States
Pfizer Investigational Site
Denver, Colorado, 80220, United States
Pfizer Investigational Site
Bridgeport, Connecticut, 06610, United States
Pfizer Investigational Site
Hartford, Connecticut, 06102, United States
Pfizer Investigational Site
New Britain, Connecticut, 06053, United States
Pfizer Investigational Site
Newark, Delaware, 19718, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, 20037, United States
Pfizer Investigational Site
Clearwater, Florida, 33756, United States
Pfizer Investigational Site
Gainsville, Florida, 32608, United States
Pfizer Investigational Site
Gainsville, Florida, 32610, United States
Pfizer Investigational Site
Hollywood, Florida, 33021, United States
Pfizer Investigational Site
Inverness, Florida, 34452, United States
Pfizer Investigational Site
Lakeland, Florida, 33805, United States
Pfizer Investigational Site
Miami, Florida, 33173, United States
Pfizer Investigational Site
Miami, Florida, 33176, United States
Pfizer Investigational Site
Ocala, Florida, 34474, United States
Pfizer Investigational Site
Orlando, Florida, 32803, United States
Pfizer Investigational Site
Port Charlotte, Florida, 33952, United States
Pfizer Investigational Site
Sarasota, Florida, 34239, United States
Pfizer Investigational Site
Stuart, Florida, 34996, United States
Pfizer Investigational Site
Tamarac, Florida, 33321, United States
Pfizer Investigational Site
The Villages, Florida, 32159, United States
Pfizer Investigational Site
Atlanta, Georgia, 30309, United States
Pfizer Investigational Site
Canton, Georgia, 30114, United States
Pfizer Investigational Site
Berwyn, Illinois, 60402, United States
Pfizer Investigational Site
Blue Island, Illinois, 60406, United States
Pfizer Investigational Site
Chicago, Illinois, 60610, United States
Pfizer Investigational Site
Chicago, Illinois, 60611, United States
Pfizer Investigational Site
Du Quoin, Illinois, 62832, United States
Pfizer Investigational Site
Evanston, Illinois, 60201, United States
Pfizer Investigational Site
Lake Forest, Illinois, 60045, United States
Pfizer Investigational Site
Marion, Illinois, 62959, United States
Pfizer Investigational Site
Pekin, Illinois, 61554, United States
Pfizer Investigational Site
Peoria, Illinois, 61603, United States
Pfizer Investigational Site
Peoria, Illinois, 61614, United States
Pfizer Investigational Site
Beech Grove, Indiana, 46107, United States
Pfizer Investigational Site
Evansville, Indiana, 47710, United States
Pfizer Investigational Site
Fort Wayne, Indiana, 46805, United States
Pfizer Investigational Site
Fort Wayne, Indiana, 46825, United States
Pfizer Investigational Site
Jeffersonville, Indiana, 47130, United States
Pfizer Investigational Site
Scottsburg, Indiana, 47170, United States
Pfizer Investigational Site
Des Moines, Iowa, 50314, United States
Pfizer Investigational Site
Iowa City, Iowa, 52242, United States
Pfizer Investigational Site
Kansas City, Kansas, 66160-7200, United States
Pfizer Investigational Site
Lathe, Kansas, 66061, United States
Pfizer Investigational Site
Overland Park, Kansas, 66213, United States
Pfizer Investigational Site
Wichita, Kansas, 67220, United States
Pfizer Investigational Site
Edgewood, Kentucky, 41017, United States
Pfizer Investigational Site
Erlanger, Kentucky, 41018, United States
Pfizer Investigational Site
Louisville, Kentucky, 40202, United States
Pfizer Investigational Site
Marrero, Louisiana, 70072, United States
Pfizer Investigational Site
New Orleans, Louisiana, 70112, United States
Pfizer Investigational Site
New Orleans, Louisiana, 70121, United States
Pfizer Investigational Site
Portland, Maine, 04102, United States
Pfizer Investigational Site
Baltimore, Maryland, 21201, United States
Pfizer Investigational Site
Baltimore, Maryland, 21204, United States
Pfizer Investigational Site
Baltimore, Maryland, 21205, United States
Pfizer Investigational Site
Baltimore, Maryland, 21208, United States
Pfizer Investigational Site
Baltimore, Maryland, 21218, United States
Pfizer Investigational Site
Baltimore, Maryland, 21224, United States
Pfizer Investigational Site
Baltimore, Maryland, 21228, United States
Pfizer Investigational Site
Baltimore, Maryland, 21229, United States
Pfizer Investigational Site
Baltimore, Maryland, 21237, United States
Pfizer Investigational Site
Baltimore, Maryland, 21287, United States
Pfizer Investigational Site
Bel Air, Maryland, 21014, United States
Pfizer Investigational Site
Westminster, Maryland, 21157, United States
Pfizer Investigational Site
Boston, Massachusetts, 02111, United States
Pfizer Investigational Site
Boston, Massachusetts, 02215, United States
Pfizer Investigational Site
Burlington, Massachusetts, 1805, United States
Pfizer Investigational Site
Dearborn, Michigan, 48126, United States
Pfizer Investigational Site
Detroit, Michigan, 48202, United States
Pfizer Investigational Site
Farmington Hill, Michigan, 48336, United States
Pfizer Investigational Site
Sterling Heights, Michigan, 48310, United States
Pfizer Investigational Site
West Bloomfield, Michigan, 48322, United States
Pfizer Investigational Site
Duluth, Minnesota, 55805, United States
Pfizer Investigational Site
Edina, Minnesota, 55435, United States
Pfizer Investigational Site
Maplewood, Minnesota, 55109, United States
Pfizer Investigational Site
Minneapolis, Minnesota, 55455, United States
Pfizer Investigational Site
Saint Paul, Minnesota, 55102, United States
Pfizer Investigational Site
Kansas City, Missouri, 64111, United States
Pfizer Investigational Site
St Louis, Missouri, 63104, United States
Pfizer Investigational Site
St Louis, Missouri, 63110-0205, United States
Pfizer Investigational Site
St Louis, Missouri, 63110, United States
Pfizer Investigational Site
St Louis, Missouri, 63117, United States
Pfizer Investigational Site
St Louis, Missouri, 63141, United States
Pfizer Investigational Site
Papillion, Nebraska, 68046, United States
Pfizer Investigational Site
Manchester, New Hampshire, 03102, United States
Pfizer Investigational Site
New Brunswick, New Jersey, 08901, United States
Pfizer Investigational Site
Albany, New York, 12208, United States
Pfizer Investigational Site
Brooklyn, New York, 11203, United States
Pfizer Investigational Site
Hawthorne, New York, 10535, United States
Pfizer Investigational Site
Manlius, New York, 13104, United States
Pfizer Investigational Site
New York, New York, 10021, United States
Pfizer Investigational Site
New York, New York, 10029, United States
Pfizer Investigational Site
New York, New York, 10032, United States
Pfizer Investigational Site
Rochester, New York, 14607, United States
Pfizer Investigational Site
Rochester, New York, 14618, United States
Pfizer Investigational Site
Rochester, New York, 14621, United States
Pfizer Investigational Site
Syracuse, New York, 13202, United States
Pfizer Investigational Site
Syracuse, New York, 13210, United States
Pfizer Investigational Site
Valhalla, New York, 10595, United States
Pfizer Investigational Site
Asheville, North Carolina, 28803, United States
Pfizer Investigational Site
Durham, North Carolina, 27710, United States
Pfizer Investigational Site
Eden, North Carolina, 27288, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27157, United States
Pfizer Investigational Site
Beachwood, Ohio, 44122, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45219, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45229, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45246, United States
Pfizer Investigational Site
Cleveland, Ohio, 44106-5038, United States
Pfizer Investigational Site
Cleveland, Ohio, 44195, United States
Pfizer Investigational Site
Columbus, Ohio, 43210, United States
Pfizer Investigational Site
Columbus, Ohio, 43221, United States
Pfizer Investigational Site
Kettering, Ohio, 45429-1221, United States
Pfizer Investigational Site
Lorain, Ohio, 44053, United States
Pfizer Investigational Site
Sandusky, Ohio, 44870, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73104, United States
Pfizer Investigational Site
Tulsa, Oklahoma, 74133, United States
Pfizer Investigational Site
Tulsa, Oklahoma, 74136-1920, United States
Pfizer Investigational Site
Tulsa, Oklahoma, 74136, United States
Pfizer Investigational Site
Eugene, Oregon, 97401, United States
Pfizer Investigational Site
Portland, Oregon, 97210, United States
Pfizer Investigational Site
Portland, Oregon, 97216, United States
Pfizer Investigational Site
Allentown, Pennsylvania, 18102, United States
Pfizer Investigational Site
Allentown, Pennsylvania, 18106-0880, United States
Pfizer Investigational Site
Lansdale, Pennsylvania, 19446, United States
Pfizer Investigational Site
Lehighton, Pennsylvania, 18235, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19104, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19107, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
Pfizer Investigational Site
Sellersville, Pennsylvania, 18960, United States
Pfizer Investigational Site
Pawtucket, Rhode Island, 02860, United States
Pfizer Investigational Site
Providence, Rhode Island, 02906, United States
Pfizer Investigational Site
Charleston, South Carolina, 29403, United States
Pfizer Investigational Site
Sioux Falls, South Dakota, 57105, United States
Pfizer Investigational Site
Sioux Falls, South Dakota, 57108, United States
Pfizer Investigational Site
Memphis, Tennessee, 38104, United States
Pfizer Investigational Site
Memphis, Tennessee, 38105, United States
Pfizer Investigational Site
Memphis, Tennessee, 38119-5209, United States
Pfizer Investigational Site
Memphis, Tennessee, 38128, United States
Pfizer Investigational Site
Nashville, Tennessee, 37205, United States
Pfizer Investigational Site
Nashville, Tennessee, 37232-6300, United States
Pfizer Investigational Site
Austin, Texas, 78756, United States
Pfizer Investigational Site
Dallas, Texas, 75235, United States
Pfizer Investigational Site
Dallas, Texas, 75246, United States
Pfizer Investigational Site
Dallas, Texas, 75390-9047, United States
Pfizer Investigational Site
Denton, Texas, 76204, United States
Pfizer Investigational Site
Houston, Texas, 77030, United States
Pfizer Investigational Site
Lackland Air Force Base, Texas, 78236-5300, United States
Pfizer Investigational Site
San Antonio, Texas, 78229, United States
Pfizer Investigational Site
Salt Lake City, Utah, 84124, United States
Pfizer Investigational Site
Burlington, Vermont, 05401, United States
Pfizer Investigational Site
Richmond, Virginia, 23249, United States
Pfizer Investigational Site
Richmond, Virginia, 23298, United States
Pfizer Investigational Site
Seattle, Washington, 98104, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, 53295, United States
Pfizer Investigational Site
St Leonards, New South Wales, 2065, Australia
Pfizer Investigational Site
Auchenflower, Queensland, 4066, Australia
Pfizer Investigational Site
Brisbane, Queensland, 4029, Australia
Pfizer Investigational Site
Chermside, Queensland, 4032, Australia
Pfizer Investigational Site
Greenslopes, Queensland, 4130, Australia
Pfizer Investigational Site
Herston, Queensland, 4029, Australia
Pfizer Investigational Site
Milton, Queensland, 4064, Australia
Pfizer Investigational Site
Adelaide, South Australia, 5000, Australia
Pfizer Investigational Site
Bedford Park, South Australia, 5042, Australia
Pfizer Investigational Site
Hobart, Tasmania, 7000, Australia
Pfizer Investigational Site
Clayton, Victoria, 3168, Australia
Pfizer Investigational Site
Parkville, Victoria, 3050, Australia
Pfizer Investigational Site
Prahran, Victoria, 3181, Australia
Pfizer Investigational Site
Nedlands, Western Australia, 6009, Australia
Pfizer Investigational Site
Feldkirch, A-6807, Austria
Pfizer Investigational Site
Oberpullendorf, A-7350, Austria
Pfizer Investigational Site
Vienna, 1100, Austria
Pfizer Investigational Site
Vienna, A-1090, Austria
Pfizer Investigational Site
Aalst, 9300, Belgium
Pfizer Investigational Site
Antwerp, B-2020, Belgium
Pfizer Investigational Site
Genk, 3600, Belgium
Pfizer Investigational Site
Genk, B-3600, Belgium
Pfizer Investigational Site
Godinne, 5530, Belgium
Pfizer Investigational Site
Leuven, 3000, Belgium
Pfizer Investigational Site
Lommel, 3920, Belgium
Pfizer Investigational Site
Neerpelt, 3910, Belgium
Pfizer Investigational Site
Calgary, Alberta, T2E 7C5, Canada
Pfizer Investigational Site
Calgary, Alberta, T2N 4N1, Canada
Pfizer Investigational Site
Edmonton, Alberta, T5R 4H5, Canada
Pfizer Investigational Site
Edmonton, Alberta, T6G 2B7, Canada
Pfizer Investigational Site
Nanaimo, British Columbia, V9S 2B8, Canada
Pfizer Investigational Site
Vancouver, British Columbia, V6R 1Y6, Canada
Pfizer Investigational Site
Victoria, British Columbia, V8T 5G4, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9, Canada
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 3A7, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, P3E 1B8, Canada
Pfizer Investigational Site
Hamilton, Ontario, L8L 2X2, Canada
Pfizer Investigational Site
London, Ontario, N6A 4G5, Canada
Pfizer Investigational Site
Ottawa, Ontario, K1Y 4W7, Canada
Pfizer Investigational Site
Toronto, Ontario, M5C 2T2, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, G7H 5H6, Canada
Pfizer Investigational Site
Montreal, Quebec, H1T 1C8, Canada
Pfizer Investigational Site
Montreal, Quebec, H2W 1R7, Canada
Pfizer Investigational Site
Montreal, Quebec, H3A 1A1, Canada
Pfizer Investigational Site
Québec, Quebec, G1R 2J6, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 5N4, Canada
Pfizer Investigational Site
St-foy, Quebec, G1V 4G2, Canada
Pfizer Investigational Site
Pessac, Cedex, 33604, France
Pfizer Investigational Site
Agen, 47000, France
Pfizer Investigational Site
Bordeaux, 33000, France
Pfizer Investigational Site
Brest, 29200, France
Pfizer Investigational Site
Clermont-Ferrand, 63003, France
Pfizer Investigational Site
Lyon, 69003, France
Pfizer Investigational Site
Marseille, 13915 Cedex 20, France
Pfizer Investigational Site
Paris, 75230, France
Pfizer Investigational Site
Rennes, 35033, France
Pfizer Investigational Site
Roubaix, 59056, France
Pfizer Investigational Site
Strasbourg, 67091, France
Pfizer Investigational Site
Toulouse, 31059, France
Pfizer Investigational Site
Toulouse, 31400, France
Pfizer Investigational Site
Berlin, 13353, Germany
Pfizer Investigational Site
Berlin, 13439, Germany
Pfizer Investigational Site
Essen, 45329, Germany
Pfizer Investigational Site
Hamburg, 20246, Germany
Pfizer Investigational Site
Schwerte, D-58239, Germany
Pfizer Investigational Site
Tostedt, 21255, Germany
Pfizer Investigational Site
Würzburg, 97070, Germany
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, D8, Ireland
Pfizer Investigational Site
Bologna, 40138, Italy
Pfizer Investigational Site
Bologna, 40139, Italy
Pfizer Investigational Site
Cuneo, 12100, Italy
Pfizer Investigational Site
Florence, 50134, Italy
Pfizer Investigational Site
Napoli, 80131, Italy
Pfizer Investigational Site
Rome, 00184, Italy
Pfizer Investigational Site
Udine, 33100, Italy
Pfizer Investigational Site
's-Hertogenbosch, 5211 NL, Netherlands
Pfizer Investigational Site
Alkmaar, 1815 JD, Netherlands
Pfizer Investigational Site
Amersfoort, 3818 ES, Netherlands
Pfizer Investigational Site
Amsterdam, 1105 AZ, Netherlands
Pfizer Investigational Site
Breda, 4818 CK, Netherlands
Pfizer Investigational Site
Eindhoven, 5623 EJ, Netherlands
Pfizer Investigational Site
Enschede, 7513 ER, Netherlands
Pfizer Investigational Site
Groningen, 9713 GZ, Netherlands
Pfizer Investigational Site
Groningen, 9728 NZ, Netherlands
Pfizer Investigational Site
Leiden, 2333 ZA, Netherlands
Pfizer Investigational Site
Nieuwegein, 3435 CM, Netherlands
Pfizer Investigational Site
Nijmegen, 6532 SZ, Netherlands
Pfizer Investigational Site
Zwolle, 8011 JW, Netherlands
Pfizer Investigational Site
Zwolle, 8025 AB, Netherlands
Pfizer Investigational Site
Johannesburg, Gauteng, 2193, South Africa
Pfizer Investigational Site
Sunninghill, Gauteng, 2157, South Africa
Pfizer Investigational Site
Bloemfontein, 9301, South Africa
Pfizer Investigational Site
Cape Town, 7405, South Africa
Pfizer Investigational Site
Cape Town, 7500, South Africa
Pfizer Investigational Site
Parow, 7505, South Africa
Pfizer Investigational Site
Córdoba, CORDOBA, 14004, Spain
Pfizer Investigational Site
Madrid, Madrid, 28007, Spain
Pfizer Investigational Site
Seville, Sevilla, 41009, Spain
Pfizer Investigational Site
Seville, Sevilla, 41013, Spain
Pfizer Investigational Site
Barcelona, 08035, Spain
Pfizer Investigational Site
Barcelona, 08036, Spain
Pfizer Investigational Site
Donostia / San Sebastian, 20014, Spain
Pfizer Investigational Site
Madrid, 28029, Spain
Pfizer Investigational Site
Madrid, 28040, Spain
Pfizer Investigational Site
Madrid, 28041, Spain
Pfizer Investigational Site
Santiago de Compostela, 15706, Spain
Pfizer Investigational Site
Valladolid, 47011, Spain
Pfizer Investigational Site
Zaragoza, 50009, Spain
Pfizer Investigational Site
Bern, 3010, Switzerland
Pfizer Investigational Site
Geneva, CH-1211, Switzerland
Pfizer Investigational Site
Lausanne, CH-1011, Switzerland
Pfizer Investigational Site
Lugano, 6900, Switzerland
Pfizer Investigational Site
Sankt Gallen, CH-9007, Switzerland
Pfizer Investigational Site
Romford, ESSEX, RM7 OBE, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, E2 9JX, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, NW10 7NS, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, SW17 0RE, United Kingdom
Pfizer Investigational Site
Aldershot, HAMPSHIRE, GU11 3RB, United Kingdom
Pfizer Investigational Site
Farnborough, KENT, BR6 7AR, United Kingdom
Pfizer Investigational Site
Blackpool, LANCASHIRE, FY3 8NR, United Kingdom
Pfizer Investigational Site
Leicester, LEICESTERSHIRE, LE3 9QP, United Kingdom
Pfizer Investigational Site
London, MIDDLESEX, HA8 0AD, United Kingdom
Pfizer Investigational Site
Coventry, West Midlands, CV1 4FH, United Kingdom
Pfizer Investigational Site
Coventry, WEST Midlands, CV2 2DX, United Kingdom
Pfizer Investigational Site
Swindon, Wiltshire, SN3 6BB, United Kingdom
Pfizer Investigational Site
Barnet, EN5 3DJ, United Kingdom
Pfizer Investigational Site
Glasgow, G11 6NT, United Kingdom
Pfizer Investigational Site
London, E1 1BB, United Kingdom
Pfizer Investigational Site
London, NW3 2PF, United Kingdom
Pfizer Investigational Site
Paisley, P1 1HR, United Kingdom
Pfizer Investigational Site
Related Publications (25)
Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17.
PMID: 17084252RESULTTunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
PMID: 38018702DERIVEDVogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
PMID: 31020900DERIVEDBangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.
PMID: 30571333DERIVEDKaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.
PMID: 29622600DERIVEDVallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.
PMID: 29618599DERIVEDOng KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.
PMID: 29358194DERIVEDPorts WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
PMID: 28573499DERIVEDBangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148.
PMID: 28379800DERIVEDStam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
PMID: 28214794DERIVEDDeedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
PMID: 27513651DERIVEDByun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.
PMID: 25835440DERIVEDArsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014.
PMID: 25531109DERIVEDDorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
PMID: 23674398DERIVEDSemb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
PMID: 22576673DERIVEDHuijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043.
PMID: 22575316DERIVEDMora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29.
PMID: 22461416DERIVEDArsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. doi: 10.1161/CIRCGENETICS.111.960252. Epub 2011 Dec 1.
PMID: 22135385DERIVEDArsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052.
PMID: 21185503DERIVEDHyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
PMID: 20130232DERIVEDWaters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502. doi: 10.1016/j.pcad.2009.01.001.
PMID: 19410683DERIVEDShepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug;83(8):870-9.
PMID: 18674471DERIVEDShah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.
PMID: 18482661DERIVEDShepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.
PMID: 18402899DERIVEDBarter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278.
PMID: 17898099DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 16, 2006
First Posted
May 18, 2006
Study Start
April 1, 1998
Study Completion
August 1, 2004
Last Updated
May 3, 2007
Record last verified: 2007-05